,
Nordicus Partners

Coming – March 19

3 Blockbuster Programs and An Uplisting To NASDAQ

Date and Time

March 19

–

12:00 PM ET / 9:00 AM

Details will be provided upon RSVP approval

About this Event

Nordicus Partners (OTCQB: NORD) is helping to build the next generation of Nordic and U.S. life sciences companies through strategic investments, operational expertise, and innovative solutions. The company is focused on transformative, scalable opportunities in high-growth sectors with unmet medical needs.

They have developed a proven 4-step value creation process: Scout, Accelerate, Acquire, and Exit. Their portfolio currently features three bio-tech innovators:
  • Oricidin is developing treatments for aggressive periodontitis
  • Bio-Convert has developed a transformative treatment for Oral Leukoplakia, a precursor to oral cancer
  • NoviThera ApS is developing a novel monoclonal antibody (MaB) therapy for psoriasis.

All three offer first-to-market solutions for multibillion dollar global markets.
The company recently applied to uplist to the NASDAQ. In their announcement the company said, the listing “will not only provide greater visibility and liquidity for our shareholders, but also strengthen our ability to attract institutional investors.”

Register today to join our online event with Nordicus, CEO Henrik Rouf, to learn more about Nordicus and their mission to foster the next generation of Nordic and U.S. Life Sciences companies.

Sign Up Today

SHARE THIS EVENT

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts and referenced statistics, contained in this presentation, including statements regarding future company strategy, operations, financial position, revenues, projected costs, plans and objectives of management, will be forward-looking statements.

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.